Menu

TORAYMYXIN®

Toraymyxin® – Polymyxin B hemoperfusion therapy – (Toray Industries Ltd., Japan) is the state-of-the-art therapy for the treatment of patients with endotoxic septic shock who are unresponsive to conventional treatment. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published demonstrating the safety and effectiveness of Polymyxin B hemoperfusion therapy.

Polymyxin B hemoperfusion therapy takes advantage of the strong endotoxin neutralizing capability of Polymyxin B intelligently immobilized to polystyrene fibers. The innovation by TORAY proposing Polymyxin B (polycationic antibiotic) therapy by means of extracorporeal hemoperfusion has provided the most effective therapy for the neutralization of endotoxin, a pathogen and potent killer, when present in the blood stream.

Toraymyxin® is the reference for the treatment of patients with endotoxic septic shock who are unresponsive to conventional therapies. With its outstanding endotoxin removal capacity, high affinity binding may remove up to 90% of circulating endotoxin after two hemoperfusion treatments. Since its introduction, more than 200,000 patients have been treated with polymyxin B hemoperfusion (PMX-HP), with a low incidence of reported adverse events (<1%) and high tolerability. More than 400 peer-reviewed articles have been published and numerous clinical studies have demonstrated that PMX-HP therapy has a positive effect on hemodynamics, organ function and survival in patients with septic shock.

Although PMX-HP therapy was designed to adsorb endotoxin, other mechanisms of immunomodulation have been demonstrated. Some of these mechanisms are caused by elimination of endotoxin, while others result from the direct adsorption of inflammatory mediators, such as activated monocytes, activated neutrophils and inactivation of circulating renal apoptotic factors. PMX-HP is currently the only therapy available to effectively neutralize both endotoxin and inflammatory mediators in patients with septic shock.

Toraymyxin® is now available in two versions:

  • PMX-20R device: for patients with adult body volume
  • PMX-05R device: for patients with reduced volume

Both devices contain 5 mg of Polymyxin B per each gram of matrix fiber guaranteeing maximum action of Polymyxin B in hemoperfusion modality.

PMX-05R is the first blood purification device conceived as complementary therapy in patients with a reduced volume affected by endotoxic septic shock, fully conformant with the high quality standards of TORAY.

Polymyxin B hemoperfusion therapy (Toraymyxin®):

  • Outstanding neutralization and removal of endotoxin
  • Selective adsorption of activated monocytes and neutrophils
  • Recovery of immune balance and microcirculation
  • Fast recovery of hemodynamics and organ dysfunction
  • Rapid reduction of vasopressors and in blood lactate level
  • Improved outcome in specific populations
  • A safe and cost-effective therapy
  • A dedicated diagnostic test available (EAA™)

More than 200,000 patients have been treated with PMX-HP worldwide and more than 400 peer-reviewed articles have been published.